Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

被引：0
|
作者：
Kang, Dongwoo [1 ]
Passarell, Julie [2 ]
Abutarif, Malaz A. [1 ]
Mendell, Jeanne [1 ]
Yin, Ophelia [1 ]
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] Cognigen Corp, Buffalo, NY USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122582
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy
    Klement, Piroska
    Fiedler, Walter
    Gabdoulline, Razif
    Dallmann, Louisa-Kristin
    Wienecke, Clara
    Schiller, Johannes
    Kandziora, Christian
    Teich, Katrin
    Heida, Bennet
    Brandes, Maximilian
    Funke, Carolin
    Wichmann, Martin
    Othman, Basem
    Chromik, Jorg
    Buettner, Konstantin
    Amberg, Stefanie
    Kebenko, Maxim
    Schlipfenbacher, Vera
    Wilke, Anne C.
    Modemann, Franziska
    Janning, Melanie
    Serve, Hubert
    Bokemeyer, Carsten
    Deppermann, Ute
    Kranich, Anne L.
    Ganser, Arnold
    Thol, Felicitas
    Heuser, Michael
    BLOOD, 2021, 138
  • [22] Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies.
    Sharma, Shringi
    Jin, Feng
    Wu, Meihua
    Robeson, Michelle
    Abella-Dominicis, Esteban
    Sharman, Jeff Porter
    Ramanathan, Srini
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
    LaCerte, Carl
    Ivaturi, Vijay
    Gobburu, Joga
    Greer, Jacqueline M.
    Doyle, L. Austin
    Wright, John J.
    Karp, Judith E.
    Rudek, Michelle A.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3592 - 3600
  • [24] Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
    Piroska Klement
    Walter Fiedler
    Razif Gabdoulline
    Louisa-Kristin Dallmann
    Clara Philine Wienecke
    Johannes Schiller
    Christian Kandziora
    Katrin Teich
    Bennett Heida
    Konstantin Büttner
    Maximilian Brandes
    Carolin Funke
    Martin Wichmann
    Basem Othman
    Joerg Chromik
    Stefanie Amberg
    Maxim Kebenko
    Vera Schlipfenbacher
    Anne Christine Wilke
    Franziska Modemann
    Melanie Janning
    Hubert Serve
    Carsten Bokemeyer
    Susann Theile
    Ute Deppermann
    Anne L. Kranich
    Arnold Ganser
    Felicitas Thol
    Michael Heuser
    Annals of Hematology, 2023, 102 : 323 - 328
  • [25] Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
    Hayato, Seiichi
    Shumaker, Robert
    Ferry, Jim
    Binder, Terri
    Dutcus, Corina E.
    Hussein, Ziad
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) : 971 - 978
  • [26] EFFICACY AND SAFETY OF QUIZARTINIB (AC220) IN PATIENTS AGE ≥60 YEARS WITH FLT3-ITD-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Doehner, H.
    Perl, A.
    Rousselot, P.
    Marie, J.
    Martinelli, G.
    Gammon, G.
    Trone, D.
    Cortes, J.
    Levis, M.
    HAEMATOLOGICA, 2013, 98 : 233 - 233
  • [27] Exposure-response analysis of venetoclax in combination with carfilzomib and dexamethasone in t(11;14)-positive relapsed/refractory multiple myeloma patients
    Badawi, Mohamed
    Engelhardt, Benjamin
    Dobkowska, Edyta
    Deng, Rong
    Kaufman, Jonathan
    Menon, Rajeev
    Salem, Ahmed Hamed
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S161 - S162
  • [28] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
    Dosne, Anne-Gaelle
    Li, Xia
    Luo, Man Melody
    Nnane, Ivo
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Sonneveld, Pieter
    Kampfenkel, Tobias
    Carson, Robin
    Amin, Himal
    Ruixo, Juan Perez
    Zhou, Honghui
    Sun, Yu-Nien
    Xu, Yan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) : 1640 - 1655
  • [29] Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM)
    Polepally, Akshanth
    Badillo, Jesus D.
    de Almeida, Carla Biesdorf
    Voorhees, Peter M.
    D'Souza, Anita
    Kumar, Shaji
    Bueno, Orlando Felix
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Menon, Rajeev
    Mensing, Sven
    Engelhardt, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Ide, Takafumi
    Osawa, Mayu
    Sanghavi, Kinjal
    Vezina, Heather E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 129 - 140
12345